Profile
Corporate information
Registration country
CellVoyant is an AI-first company developing closed-loop optimisation platforms for cell and tissue manufacturing based on their three products - FateView, FateCast, and FateSim. The products allow for label free (i.e., no need for genetic mutation or cell staining) identification, assessment, selection, prediction, and control of cell state and fate (i.e., future differentiation). The company so far has focused on induced Pluripotent Stem Cells (iPSCs). However, their end-to-end deep learning platform allows for generalisation across any cell types. The tech stack is composed of label free imaging and computer vision for cell identification with the key part of their techstack being the Bayesian Neural Networks that allow for time series analysis and quantification of all the physical and biological (e.g., growth factors) to steer the cells to a certain direction of interest. In other words, combining all three products, CellVoyant wants to develop autonomous driving of cell manufacturing.
Funding
Funding rounds
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Verve Capital Partners AG | Switzerland | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Octopus Ventures Ltd | United Kingdom | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Air Street Capital | Initial investment. Round participant. |
Investor | Profile | Country | Notes | |
---|---|---|---|---|
Horizons Ventures | Venture capital firm owned by Hong Kong billionaire Li Ka-shing | Hong Kong SAR China | Initial investment. Round participant. |
Cap Table
Current and past shareholders
Investor | Round | |
---|---|---|
Air Street Capital |
N/A | |
Horizons Ventures Venture capital firm owned by Hong Kong billionaire Li Ka-shing |
N/A | |
Octopus Ventures Ltd |
N/A | |
Verve Capital Partners AG |
N/A |